Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

LGND 57.03 -0.39 (-0.68%)
price chart
Ligand Pharmaceuticals Inc Stock Downgraded (LGND)
LIGAND PHARMACEUTICAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Related articles »  
Ligand Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ...
In trading on Monday, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) crossed above their 200 day moving average of $56.27, changing hands as high as $56.60 per share.
Why Ligand Pharmaceuticals Inc. Shares Popped
What: Shares of Ligand Pharmaceuticals (NASDAQ: LGND ) , a biotechnology company that develops and acquires royalty rights to pharmaceutical products, gained as much as 15% after the company reported better than expected fourth-quarter results and ...
Related articles »  
Brokerage Firm Price Target on Ligand Pharmaceuticals Inc.
Deutsche Bank initiates coverage on Ligand Pharmaceuticals Inc. (NASDAQ:LGND).The analysts at the brokerage house have a current rating of Buy on the counter.
Ligand Pharmaceuticals Inc. Reports Insider Transaction
Ligand Pharmaceuticals Inc. (NASDAQ:LGND), The Securities and Exchange Commission has divulged in a Form 4 filing that the VP, Gen.
Ligand Pharmaceuticals Inc. (LGND) Largest Owner Sells Shares
Raising prospects for a continued deterioration in the stock price of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), the largest shareholder in the company has moved to unload shares of the troubled company in a private transactions.
Related articles »  
Ligand Pharmaceuticals Inc. Stock Upgraded (LGND)
This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, LIGAND PHARMACEUTICAL INC's return on equity exceeds that of both the industry average and the S&P 500.
Related articles »  
Ligand Pharmaceuticals Given a $116.00 Price Target at Roth Capital (LGND)
Ligand Pharmaceuticals Inc. logo Roth Capital set a $116.00 price target on Ligand Pharmaceuticals (NASDAQ:LGND) in a research report sent to investors on Wednesday morning.
Lemeson Ups Ligand Pharmaceuticals Inc. (LGND) Short
Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and appended with additional concerns its initial June 16, 2014 research ...
Ligand Pharmaceuticals: Appendix  Seeking Alpha
Related articles »  
Ligand Pharmaceuticals Inc. (LGND), Inovio Pharmaceuticals Inc (INO), & Tejon ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Inovio Pharmaceuticals Inc (NASDAQ:INO) are two stocks from the pharma space that have recently seen insiders buying shares in large quantities.
Related articles »